Your browser is no longer supported. Please, upgrade your browser.
ALNA Allena Pharmaceuticals, Inc. monthly Stock Chart
ALNA [NASD]
Allena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.27 Insider Own4.28% Shs Outstand36.26M Perf Week8.96%
Market Cap54.68M Forward P/E- EPS next Y-0.78 Insider Trans0.00% Shs Float17.95M Perf Month13.18%
Income-33.90M PEG- EPS next Q-0.21 Inst Own45.20% Short Float8.01% Perf Quarter6.57%
Sales- P/S- EPS this Y-24.20% Inst Trans-0.61% Short Ratio1.21 Perf Half Y-33.94%
Book/sh0.50 P/B2.92 EPS next Y18.70% ROA-114.20% Target Price- Perf Year-27.72%
Cash/sh0.80 P/C1.82 EPS next 5Y- ROE-210.80% 52W Range0.52 - 3.39 Perf YTD-46.52%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-56.93% Beta-
Dividend %- Quick Ratio8.00 Sales past 5Y- Gross Margin- 52W Low178.10% ATR0.10
Employees22 Current Ratio8.00 Sales Q/Q- Oper. Margin- RSI (14)53.93 Volatility5.37% 7.36%
OptionableNo Debt/Eq0.54 EPS Q/Q60.90% Profit Margin- Rel Volume0.60 Prev Close1.38
ShortableYes LT Debt/Eq0.54 Earnings- Payout- Avg Volume1.19M Price1.46
Recom1.70 SMA205.38% SMA503.31% SMA200-3.63% Volume716,273 Change5.80%
Jun-01-20Initiated H.C. Wainwright Buy $10
Jul-10-19Resumed Credit Suisse Outperform
Jan-18-19Initiated Robert W. Baird Outperform $20
Dec-21-18Resumed B. Riley FBR Buy
Nov-08-18Resumed Jefferies Buy
Apr-25-18Initiated B. Riley FBR, Inc. Buy $23.50
Apr-02-18Initiated ROTH Capital Buy $61
Nov-24-20 08:00AM  
Nov-09-20 08:00AM  
Nov-03-20 08:01AM  
Oct-21-20 11:58AM  
Oct-14-20 11:32AM  
Oct-06-20 12:00PM  
Oct-05-20 08:00AM  
Sep-30-20 08:00AM  
Sep-08-20 08:00AM  
Sep-03-20 08:00AM  
Aug-05-20 08:00AM  
Aug-04-20 08:00AM  
Jul-27-20 08:48PM  
04:53PM  
Jul-16-20 03:27PM  
Jun-15-20 07:12PM  
Jun-03-20 01:15PM  
Jun-02-20 07:45AM  
May-26-20 08:00AM  
May-13-20 08:00AM  
Apr-22-20 12:00PM  
Mar-18-20 12:00PM  
Mar-16-20 08:00AM  
Feb-24-20 08:00AM  
Feb-13-20 08:05AM  
Feb-12-20 07:00AM  
Jan-28-20 01:48PM  
Jan-14-20 12:00PM  
Dec-16-19 01:45PM  
Dec-05-19 07:14AM  
Dec-04-19 05:00PM  
Nov-25-19 08:00AM  
Nov-18-19 06:19AM  
Nov-13-19 08:01AM  
Nov-08-19 08:14AM  
Nov-07-19 06:55AM  
Oct-17-19 08:00AM  
Oct-08-19 09:00AM  
Sep-16-19 08:00AM  
Sep-11-19 08:00AM  
Aug-29-19 08:00AM  
Aug-07-19 08:00AM  
Aug-06-19 08:00AM  
Aug-02-19 11:46AM  
Aug-01-19 11:55AM  
Jul-31-19 09:05AM  
Jul-29-19 10:04AM  
09:43AM  
Jul-26-19 10:53AM  
09:13AM  
09:12AM  
Jul-25-19 07:37AM  
Jun-27-19 08:45PM  
Jun-21-19 08:00AM  
Jun-15-19 12:38PM  
Jun-04-19 08:00AM  
May-30-19 08:00AM  
May-08-19 09:00AM  
08:00AM  
Apr-17-19 09:02AM  
08:01AM  
Mar-27-19 08:00AM  
Mar-07-19 08:01AM  
Mar-05-19 08:00AM  
Jan-04-19 08:00AM  
Jan-02-19 08:00AM  
Dec-23-18 09:21PM  
Nov-19-18 08:25AM  
Nov-07-18 08:00AM  
Nov-06-18 04:01PM  
Oct-25-18 08:00AM  
Oct-22-18 08:00AM  
Oct-18-18 08:00AM  
Sep-25-18 08:00AM  
Aug-07-18 04:01PM  
08:00AM  
Jul-27-18 07:36AM  
Jul-12-18 07:48AM  
Jun-19-18 08:00AM  
Jun-11-18 08:00AM  
May-30-18 08:00AM  
May-08-18 08:00AM  
Apr-20-18 05:54PM  
Apr-04-18 11:21AM  
Mar-30-18 02:31PM  
Mar-27-18 08:00AM  
Mar-07-18 08:00AM  
Mar-06-18 08:00AM  
Feb-23-18 03:03PM  
Feb-14-18 09:38PM  
Feb-05-18 10:00AM  
Nov-24-17 02:25PM  
Nov-09-17 07:35PM  
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was founded in 2011 and is headquartered in Newton, Massachusetts.
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 FINVIZ.com. All Rights Reserved.